Trial Profile
An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Janssen R&D Ireland
- 17 Apr 2020 Status changed from active, no longer recruiting to completed.
- 29 Oct 2019 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.
- 16 Apr 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.